Renalytix Plc
RENX.L · LSE
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | £1 | £1 | £1 | £1 |
| % Growth | 39.7% | -10.9% | 9.5% | – |
| Cost of Goods Sold | £0 | £0 | £1 | £1 |
| Gross Profit | £0 | £0 | £0 | -£0 |
| % Margin | 54.6% | 19.2% | 6.1% | -12.3% |
| R&D Expenses | £0 | £1 | £1 | £2 |
| G&A Expenses | -£1 | £3 | £4 | £7 |
| SG&A Expenses | -£1 | £3 | £4 | £4 |
| Sales & Mktg Exp. | £0 | £0 | £0 | -£3 |
| Other Operating Expenses | £5 | £0 | £0 | £0 |
| Operating Expenses | £4 | £4 | £6 | £6 |
| Operating Income | -£3 | -£4 | -£6 | -£6 |
| % Margin | -471.2% | -784.1% | -942.8% | -1,146.9% |
| Other Income/Exp. Net | -£0 | -£1 | -£2 | -£2 |
| Pre-Tax Income | -£4 | -£5 | -£7 | -£8 |
| Tax Expense | -£0 | £0 | £0 | £0 |
| Net Income | -£4 | -£5 | -£7 | -£8 |
| % Margin | -532.5% | -905.7% | -1,207.2% | -1,447.3% |
| EPS | -0.04 | -0.045 | -0.051 | -0.08 |
| % Growth | 10.7% | 12.7% | 36% | – |
| EPS Diluted | -0.04 | -0.045 | -0.051 | -0.079 |
| Weighted Avg Shares Out | 97 | 106 | 102 | 97 |
| Weighted Avg Shares Out Dil | 97 | 106 | 103 | 98 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | -£8 | -£4 | -£5 | -£6 |
| % Margin | -1,029.1% | -772.4% | -932.6% | -1,134% |